"Regarding his two ascension lines (orange vs. purple), he predicted the slower of the two, which may still prove to accurate. For now, however, it seems that were are on the faster ascension line."
Berk is more than capable of speaking for himself, but I will point out that he did not "predict" a longer term ascension to considerably higher level. What he did was point out two past patterns of rising share price. He stopped short of predicting either was going to occur, but gave his opinion that the slower ascension was more likely than the rapid version.
2018 with the sharply dropping share price and the caustic commentary on this message board was disheartening. I hate feeling like a bagholder. Hopefully 2019 will be better. I am cautiously optimistic, but the last year was a good lesson in humility and a reminder that there are no "sure things" in biotech. I don't foresee any short squeezes or moonshots in Portola's future, just hopefully constructive rising revenue from A and a roadmap for C's pivotal trial.